

SARS-CoV-2 S Recombinant Antibody

(Catalog # A73672)

Background

Recombinant anti-SARS-CoV-2 spike Mouse ScFv is expressed from 293 cells (HEK293) with a human IgG1 Fc tag on C-terminal.

Description

SARS-CoV-2 S Recombinant Antibody. Unconjugated. Raised in: Mouse.

Formulation

Preservative: 0.03% Proclin 300: 50% Glycerol, 0.01M PBS, PH 7.4.

Specificity

SARS-CoV-2

Isotype

Mouse scFv fusion with human IgG1 Fc

Uniprot ID

P0DTC2

Purification

Affinity Chromatography

Immunogen

Recombinant Human Novel Coronavirus Spike glycoprotein (S) (16-685aa)

Storage


Shipped at 4°C. Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Alternative Names



S, S1, S1-RBD, Spike glycoprotein

Application

ELISA, GICA, Neutralization; Recommended dilution: ELISA:1:10000-1:50000, GICA:1:500-1:5000, Neutralising:1:50-1:10000




The Binding Activity of SARS-CoV-2-S Antibody with SARS-CoV-2-S. Activity: Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2-S at 2 µg/ml can bind SARS-CoV-2-S Antibody, the EC₅₀ is 42.83 ng/ml [$\log(42.83) = 1.63$ as displayed in graph].




The Binding Activity of SARS-CoV-2-S Antibody with SARS-CoV-2-S1-RBD. Activity: Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2-S1-RBD at 2 µg/ml can bind SARS-CoV-2-S Antibody, the EC50 is 29.51 ng/ml [$\log(29.51) = 1.47$ as displayed in graph].

Binding signal of SARS-CoV-2-S1-RBD and ACE2 protein-HRP conjugate was inhibited by SARS-CoV-2 S Recombinant Antibody with the IC50 is 23.32 nM.



Binding signal of SARS-CoV-2-S1-RBD and ACE2 protein-HRP conjugate was inhibited by SARS-CoV-2 S Recombinant Antibody with the IC50 is 2.38 µg/ml.



ELISA: Immobilize proteins from various types of CoVs at concentration of 2 µg/ml on solid substrate, then react with SARS-CoV-2-S Antibody at concentration of 100 µg/ml, 10 µg/ml, and 1 µg/ml. It shows the SARS-CoV-2-S Antibody is specific for SARS-CoV-2-S1-RBD protein, without any cross-reactivity with MERS-CoV, SARS-CoV, HCoV-OC43 or HCoV-229E.